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Introduction
Many schizophrenic patients show progressive cortical atrophy in some brain regions [19, 31] , but the precise mechanism of these progressive changes remains unknown. Postmortem reports have described no gliosis, but a high Bax / Bcl-2 ratio with a normal caspase 3 level in chronic schizophrenia, implying that an apoptotic process in the chronic patients plays an important role in progressive cortical atrophy from prodrome to several years after the first psychotic episode in schizophrenia [10, 15] . Smaller somal volume and decreased spine density, dendritic length, and terminals than in normal controls, which are seen in schizophrenia [10] , are similarly induced in high-dose amphetamine-induced sensitized animals [29] . A toxic dosage regimen of METH induces apoptosis in cortical neurons in the medial prefrontal cortex (mPFC) [17] .
Chronic abuse of METH, which increases extracellular dopamine (DA) levels by releasing cytoplasmic DA [7, 28] , engenders positive schizophrenia-like symptoms such as hallucinations and delusions, but it rarely induces so-called negative symptoms such as flattened affect and social withdrawal. The METH-induced psychosis can therefore be used as a model for treatment-responsive schizophrenia [16] because positive symptoms are known to respond well to typical antipsychotics [30] , which mainly antagonize DA D 2 receptors. However, a psychostimulant can induce psychotic symptoms, which are resistant to DA D 2 receptor antagonists [5] .
Our group has demonstrated that a single administration of METH, at 2.5 mg/kg, increases the extracellular glutamate levels in the mPFC [2] and the nucleus accumbens (NAC) [13, 14] . Furthermore, repeated administration of METH (2.5 mg/kg) induces apoptosis in the mPFC. Atypical antipsychotics such as olanzapine and risperidone, which block METH (2.5 mg/kg)-induced extracellular glutamate increases in the mPFC, prevent apoptosis in this region [2] , suggesting that the METH (2.5 mg/kg)-induced glutamate increase in the mPFC indicates apoptosis induced by repeated administration of METH (2.5 mg/kg) in this region.
Clinically, even if many schizophrenic patients respond well to DA D 2 receptor antagonist during their first psychotic episode, some later become resistant to DA D 2 receptor antagonists [27] . The search for a treatment to prevent pathophysiological development in schizophrenia is important. We speculate that drugs such as those described above (olanzapine and risperidone) block METH-induced behavioral and histological changes in rats that are commonly observed in schizophrenia and thereby have effects that prevent the progressive pathophysiology associated with schizophrenia.
Lamotrigine (LTG) is known as an anticonvulsant [18] and mood stabilizer [12] . In addition, a clinical trial demonstrated that administration of LTG along with stable clozapine exhibited a beneficial effect on the psychopathological symptoms of clozapine-resistant schizophrenic patients [32] . Our recent report described that prepulse inhibition deficit induced by repeated METH is prevented by repeated LTG co-administration and that it is recovered by acute LTG administration [24] . However, the effects of LTG on METH-induced glutamate release and apoptosis remain unknown.
In this study, the effects of LTG (30 mg/kg) on METH (2.5 mg/kg)-induced increase in extracellular glutamate levels in the mPFC were first examined. Then, the effect of repeated co-administration of LTG (30 mg/kg) on apoptosis induced by repeated administration of METH (2.5 mg/kg) was examined. If LTG prevents METH-induced changes, then it might be a promising treatment strategy to prevent longitudinal pathophysiological progression of schizophrenia. For this study, METH (Dainippon Sumitomo Pharma Co. Ltd., Japan) was dissolved in sterile physiological saline and injected subcutaneously at a volume of 1 ml/kg; LTG (a gift from GlaxoSmithKline, U.K.) was dissolved in 10 ml of distilled water with 10 drops of 0.1 N HCl. It was then injected intraperitoneally at a volume of 4 ml/kg. Vehicles for METH and LTG were saline (1 ml/kg) and approximately 0.002 N HCl in distilled water (4 ml/kg), respectively. This study used dosages of METH (2.5 mg/kg) and LTG (30 mg/kg) that were chosen after considering the results obtained in previous studies [2, 24] .
Materials and Methods

Experiment
In experiment 1, we examined the effects of LTG (30 mg/kg) on METH (2.5 mg/kg)-induced delayed increases in glutamate levels in the mPFC. Rats were implanted stereotaxically under pentobarbital anesthesia (30 mg/kg, i.p.) with a G-4 guide cannula (Eicom Corp., Kyoto, Japan) leading to the surface of mPFC (A: +3.0 mm, L: 0.8 mm, DV: -1.8 mm) [26] . A dialysis probe (BDP-IV-03; Eicom Corp., Kyoto, Japan) was inserted into the guide cannula so that 3.0 mm of the probe was exposed to the tissue of the mPFC. On the next day, in freely moving rats, following initial perfusion for 1.5 h, samples were obtained every 20 min at the flow rate of 2 µl/min. Then LTG was administered i.p. 120 min after METH s.c.
At the end of the microdialysis study, rat brains were removed. Probe placement was verified microscopically; the success rate in this study was higher than 95%.
Glutamate levels were measured and analyzed as described in previous reports [1, 3] .
In experiment 2, we examined the effects of repeated administration of followed by Bonferroni's post-hoc test to determine significant differences between the different groups. Differences were considered significant at p < 0.05.
Results
Results show that METH (2.5 mg/kg), but not saline, induced delayed increases in extracellular glutamate levels in the mPFC. Post-treatment with LTG (30 mg/kg) inhibited the METH (2.5 mg/kg)-induced delayed increases in glutamate levels, but had no effect on extracellular glutamate levels after saline 
Discussion
In the mPFC, METH (2.5 mg/kg) increased extracellular glutamate levels, which is consistent with the results of our previous studies that demonstrated METH-induced delayed increases in extracellular glutamate levels in the mPFC
[2] and NAC [13, 14] , which might play an important role in the development of repeated METH-induced PPI disruption and behavioral cross sensitization to an NMDA receptor antagonist, MK-801. In this study, LTG (30 mg/kg) administered 120 min after METH (2.5 mg/kg) injection blocked the METH-induced glutamate increase. Similarly, a report of a previous study described that that LTG reduced veratridine-evoked release of glutamate in the hippocampus [4] . Although the mechanism of this blockade by LTG remains unclear, LTG might reduce glutamate release by exerting an inhibitory effect on sodium channels [22, 33] .
METH can cause cell death not only via apoptotic, but also via necrotic mechanisms [11] . In this study, repeated administration of METH induced apoptosis in the mPFC, consistent with previous studies [2, 9, 17].
The mechanism of METH-induced apoptosis is not well known; this apoptosis might result from many factors such as oxidants, reactive oxygen, and NO oxidative stress and cell death [21] . It also prevents enhancement of NO generation and release [6, 23] . Therefore, not only the effect of LTG to block the METH-induced delayed increases in extracellular glutamate levels in the mPFC, but also other above-described effects might produce the blockade of apoptosis development in this area.
Associated with the overt onset of schizophrenia, progressive pathophysiology such as brain atrophy is strikingly advanced [20, 31] . However, the precise mechanism of these progressive changes remains unknown. These changes might be a peculiarity that is common to progressive pathophysiology in schizophrenia and METH-induced behavioral and histological changes, 
